Preliminary updated results of a phase I/II trial using trimodality therapy in patients with post-prostatectomy high risk pathologic (p) T2-3N0M0 prostate cancer

被引：0

作者：

Kumar, Parvesh

Van Veldhuizen, Peter J.

Thompson, Mark

Shen, Xinglei

Coster, James

Pinskl, Jacek

机构：

[1] Univ Kansas, Sch Med, Dept Radiat Oncol, Kansas City, KS USA

[2] Univ Kansas, Sch Med, Div Med Oncol, Westwood, KS USA

[3] Univ So Calif, Keck Sch Med, Div Med Oncol, Los Angeles, CA 90033 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.e16084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16084

引用

页数：1

共 49 条

[31] A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403)-Long term follow-up results.
Nagata, Yasushi
Hiraoka, Masahiro
Shibata, Taro
Onishi, Hiroshi
Kokubo, Masaki
Karasawa, Katsuyuki
Shioyama, Yoshiyuki
Onimaru, Rikiya
Kunieda, Etsuo
Ishikura, Satoshi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)
Onimaru, Rikiya
Shirato, Hiroki
Shibata, Taro
Hiraoka, Masahiro
Ishikura, Satoshi
Karasawa, Katsuyuki
Matsuo, Yukinori
Kokubo, Masaki
Shioyama, Yoshiyuki
Matsushita, Haruo
Ito, Yoshinori
Onishi, Hiroshi
RADIOTHERAPY AND ONCOLOGY, 2015, 116 (02) : 276 - 280
[33] Early Outcomes for A Single-Arm Phase I/II Trial of Selective Avoidance of Nodal VolumEs at Minimal Risk (SAVER) in the Contralateral N0 Neck of Patients with p16-Positive Oropharynx Cancer
Molitoris, J. K.
Witek, M. E.
Ferris, M. J.
Kitzmiller, K.
Krc, R. F.
Tyer, T. N.
Jatczak, J.
Lehman, K.
Cullen, K. J.
Taylor, R.
Wolf, J.
Moyer, K. F.
Regine, W. F., Jr.
Bentzen, S. M.
Mehra, R.
Hatten, K.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E11 - E12
[34] 5-year results of cisplatin-elpirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients:: A multicentre phase II study
Barni, S.
Visin, M.
Piazza, E.
Ionta, M. T.
Ardizzoia, A.
Arnoldi, E.
Fava, S.
Pinotti, G.
Torretta, F.
Corradini, G.
Villa, S.
Nosenzo, A. M.
Massidda, B.
Cazzaniga, M. E.
ANTICANCER RESEARCH, 2007, 27 (4C) : 3019 - 3024
[35] Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).
Yorozu, Atsunori
Namiki, Mikio
Saito, Shiro
Egawa, Shin
Yaegashi, Hiroshi
Hiroyuki, Konaka
Momma, Tetsuo
Fukagai, Takashi
Tanaka, Nobumichi
Ohashi, Toshio
Takahashi, Hiroyuki
Mizokami, Atsushi
Nakagawa, Yoko
Kikuchi, Takashi
Stone, Nelson
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[36] Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial
McKay, Rana R.
Xie, Wanling
Yang, Xiaoyu
Rathkopf, Dana E.
Laudone, Vincent Paul
Bubley, Glenn
Einstein, David Johnson
Chang, Peter
Wagner, Andrew
Kane, Christopher J.
Parsons, J. Kellogg
Preston, Mark A.
Kilbridge, Kerry L.
Chang, Steven Lee
Choudhury, Atish Dipankar
Quoc-Dien Trinh
Pomerantz, Mark
Kibel, Adam S.
Taplin, Mary Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
Maeng, Hoyoung M.
Wood, Lauren Virginia
Moore, Brittni
Bagheri, Mohammadhadi H.
Webb, Santhana
England, Lee
Martinez, Giselle
Steinberg, Seth M.
Pack, Svetlana
Stroncek, David
Morris, John Charles
Terabe, Masaki
Berzofsky, Jay A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[38] Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study JCOG0701)
Kodaira, T.
Kagami, Y.
Shibata, T.
Shikama, N.
Nishimura, Y.
Ishikura, S.
Nakamura, K.
Saito, Y.
Matsumoto, Y.
Teshima, T.
Ito, Y.
Akimoto, T.
Nakata, K.
Toshiyasu, T.
Nakagawa, K.
Nagata, Y.
Nishimura, T.
Uno, T.
Kataoka, M.
Yorozu, A.
Hiraoka, M.
ANNALS OF ONCOLOGY, 2018, 29 (04) : 992 - 997
[39] Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA
Shipley, W. U.
Seiferheld, W.
Lukka, H.
Major, P.
Heney, N. M.
Grignon, D.
Sartor, O.
Patel, M.
Bahary, J. P.
Zietman, A. L.
Pisansky, T. M.
Zeitzer, K. L.
Lawton, C. A. F.
Feng, F. Y.
Lovett, R. D.
Balogh, A.
Souhami, L.
Rosenthal, S. A.
Kerlin, K. J.
Sandler, H. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (01): : 3 - 3
[40] Design, development of water tank-type lung phantom and dosimetric verification in institutions participating in a phase I study of stereotactic body radiation therapy in patients with T2N0M0 non-small cell lung cancer: Japan Clinical Oncology Group trial (JCOG0702)
Nishio, Teiji
Shirato, Hiroki
Ishikawa, Masayori
Miyabe, Yuki
Kito, Satoshi
Narita, Yuichirou
Onimaru, Rikiya
Ishikura, Satoshi
Ito, Yoshinori
Hiraoka, Masahiro
JOURNAL OF RADIATION RESEARCH, 2014, 55 (03) : 600 - 607

← 1 2 3 4 5 →